Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

A Discussion on the Past, Present, and Future Promise of Gene Editing with Fyodor Urnov, PhD
45:46

How rare diseases are shaping therapeutic innovation with Jennifer Adair, Claire Booth,Terry Flotte and Donald Kohn
34:19

A Full-Circle Journey at Stanford: Get to Know ASGCT President Matthew Porteus, PhD
35:44